Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance
- Laying out the development and vision of STRO-004 leveraging enhanced antibody engineering and linker-payload design to translate into impactful clinical performance against existing ADC therapies
- Exploring brand-new Phase I clinical safety and PK data targeting Tissue Factor, contextualized with how well STRO-004 translated from cyno monkey preclinical data, to understand ADC clinical benefit and enhanced therapeutic index
- Highlighting rationale, development and the power of dual payload ADCs to subvert patient resistance mechanisms to single payload ADCs